Company Overview
Repare Therapeutics Inc. operates as a clinical-stage precision oncology company focused on the discovery and development of therapeutics within Switzerland and the United States. The enterprise leverages its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to identify and advance cancer therapies designed to treat specific conditions. This company functions within the Healthcare sector, specifically the Biotechnology industry, which implies a business model centered on high-risk research and development with significant regulatory hurdles before commercialization. In terms of scale, Repare Therapeutics holds a market capitalization of $114.24M, generates annual revenue of $11.87M, and employs 129 individuals. These figures indicate that the company is a small-cap entity with limited revenue generation relative to its market valuation, suggesting a position typical for early-stage biotechnology firms where investor capital often exceeds current cash flow from operations to fund ongoing clinical trials and operational expansion.
Financial Health
The company reported revenue of $11.87M for the trailing twelve months, while the net income stood at -$72,200,000 and EBITDA reached -$76,462,000. The substantial gap between the positive revenue of $11.87M and the negative net income of -$72,200,000 reveals a cost structure characterized by heavy research and development expenditures that significantly outpace gross sales, a common trait in clinical-stage biotechnology. Free cash flow for the period was -$42,824,248, indicating that the company is burning cash at a rate that requires external financing or existing reserves to sustain operations without generating immediate liquidity. The gross margin is reported at 403.4%, which in a biotechnology context often reflects high revenue per unit or specific accounting treatments for R&D expenses before grossing them up, while the operating margin stands at -3.7% and the profit margin is 0.0%. These negative or zero margins demonstrate that the company is currently operating at a loss on an operating and net basis, relying on future commercial success to achieve profitability. The company holds $112.60M in cash against $342,000 in debt, resulting in a debt-to-equity ratio of 0.30. This balance sheet composition is highly conservative, as the cash reserves vastly exceed the minimal debt obligations, providing a substantial buffer against financial distress. Furthermore, the current ratio is 10.71, a metric that indicates exceptional short-term liquidity and an overwhelming ability to cover current liabilities with available current assets. Return on Equity is -49.8% and Return on Assets is -29.7%, metrics that reveal that management has not yet generated positive returns on the capital invested, reflecting the inherent losses associated with the development phase of precision oncology therapeutics.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of positive net income, while the forward P/E is listed at -0.89. The absence of a positive trailing P/E combined with a negative forward P/E implies that earnings are currently negative and the market is pricing the stock based on future expectations rather than current profitability. The price-to-book ratio is 0.99, indicating that the market values the company at roughly equal to its book value, which suggests no significant market premium is being applied over the tangible assets recorded on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 9.62 and an EV/EBITDA of -0.02. These alternative metrics suggest that the stock is priced primarily on its revenue generation potential and future pipeline value, rather than current earnings power or cash flow multiples. The 52-week high is $2.66 and the 52-week low is $0.89. Without a specific current price provided in the source data, the trading range establishes a volatility band where the stock has fluctuated between these bounds over the last year. The beta is 0.96, which means the stock's price volatility moves in line with the broader market, exhibiting slightly less sensitivity than a beta greater than 1.0 but maintaining standard equity risk relative to the market index.
Growth & Income
Revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, as the company is in a clinical-stage development phase where historical growth rates are not yet established. The inability to calculate a year-over-year growth rate implies that the company is currently focused on initiating revenue streams or has not yet achieved consistent commercial sales to establish a growth trajectory. As a non-dividend payer, the company does not distribute a dividend yield, which is N/A, and maintains a payout ratio of 0.0%. This lack of dividend payments indicates that the company reinvests all available earnings and cash reserves into research, development, and clinical trials rather than returning capital to shareholders. Consequently, the overall growth and income profile is defined by zero current income generation and a reliance on capital markets to fund the expansion of its oncology pipeline rather than organic profitability or shareholder distributions.